Fidelity Investments’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-299,376
| Closed | -$36.1M | – | 5668 |
|
|
2023
Q1 | $36.1M | Sell |
299,376
-132,100
| -31% | -$15.9M | ﹤0.01% | 1375 |
|
|
2022
Q4 | $49.6M | Buy |
431,476
+144,800
| +51% | +$16.6M | ﹤0.01% | 1259 |
|
|
2022
Q3 | $29.3M | Sell |
286,676
-267,200
| -48% | -$27.3M | ﹤0.01% | 1469 |
|
|
2022
Q2 | $56.2M | Buy |
553,876
+45,976
| +9% | +$4.67M | 0.01% | 1203 |
|
|
2022
Q1 | $59.1M | Buy |
507,900
+46,500
| +10% | +$5.41M | ﹤0.01% | 1325 |
|
|
2021
Q4 | $52.5M | Buy |
+461,400
| New | +$52.5M | ﹤0.01% | 1408 |
|
|
2020
Q4 | – | Sell |
-402,400
| Closed | -$44.8M | – | 4395 |
|
|
2020
Q3 | $44.8M | Buy |
402,400
+132,400
| +49% | +$14.7M | ﹤0.01% | 1235 |
|
|
2020
Q2 | $28.3M | Buy |
+270,000
| New | +$28.3M | ﹤0.01% | 1406 |
|